Compare BBSI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | NTLA |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.4M | 986.9M |
| IPO Year | 1993 | 2016 |
| Metric | BBSI | NTLA |
|---|---|---|
| Price | $38.14 | $10.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $45.50 | $19.83 |
| AVG Volume (30 Days) | 161.5K | ★ 3.6M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 10.03 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,223,992,000.00 | $57,528,000.00 |
| Revenue This Year | $10.70 | $1.96 |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | $18.17 | ★ N/A |
| Revenue Growth | 9.64 | ★ 33.52 |
| 52 Week Low | $33.01 | $5.90 |
| 52 Week High | $49.65 | $28.25 |
| Indicator | BBSI | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 58.76 |
| Support Level | $36.73 | $8.94 |
| Resistance Level | $37.47 | $9.62 |
| Average True Range (ATR) | 0.81 | 0.50 |
| MACD | 0.23 | 0.26 |
| Stochastic Oscillator | 91.62 | 75.24 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.